Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J G Nutt

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
Neurology|May 1, 1994
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patientsJ G Nutt, W R Woodward, R M Beckner, et al.
Annals of Neurology|June 9, 1999
ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's diseaseO Rascol, O Blin, C Thalamas, et al.
Archives of Neurology|February 15, 2001
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson diseaseO Rascol, J G Nutt, O Blin, et al.
BMC Neurology|October 27, 2015
Do cognitive measures and brain circuitry predict outcomes of exercise in Parkinson Disease: a randomized clinical trialL A King, D S Peterson, M Mancini, et al.
Neurology|January 15, 2003
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PDJ G Nutt, K J Burchiel, C L Comella, et al.
Parkinsonism & Related Disorders|November 5, 2013
Mobility, mood and site of care impact health related quality of life in Parkinson's diseaseJ G Nutt, A D Siderowf, M Guttman, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
Neurology|May 1, 1994
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patientsJ G Nutt, W R Woodward, R M Beckner, et al.
Annals of Neurology|June 9, 1999
ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's diseaseO Rascol, O Blin, C Thalamas, et al.
Archives of Neurology|February 15, 2001
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson diseaseO Rascol, J G Nutt, O Blin, et al.
BMC Neurology|October 27, 2015
Do cognitive measures and brain circuitry predict outcomes of exercise in Parkinson Disease: a randomized clinical trialL A King, D S Peterson, M Mancini, et al.
Neurology|January 15, 2003
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PDJ G Nutt, K J Burchiel, C L Comella, et al.
Parkinsonism & Related Disorders|November 5, 2013
Mobility, mood and site of care impact health related quality of life in Parkinson's diseaseJ G Nutt, A D Siderowf, M Guttman, et al.
Pageof 13